CBIA - Canopus BioPharma Incorporated

Canopus BioPharma Incorporated

233 Wilshire Boulevard
Suite 700
Santa Monica, CA 90401
United States
353-627-8674

Sector(s): Financial Services
Industry: Shell Companies
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Patrick T. Prendergast	Chairman & CEO	N/A	N/A	N/A
Mr. Leo J. Prendergast	COO & Director	N/A	N/A	N/A
Mr. Andries J. Lategan B.Pharm, M.Sc, Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Elizabeth Shanahan B.Sc. (Hon)	Pres of Oncology Division	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and changed its name in 2007. Canopus BioPharma Incorporated is based in Santa Monica, California.

Corporate Governance

Canopus BioPharma Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.